Methods and compositions for somatic cell proliferation and viability

Patent metadata

Field	Value
Publication number	US-10214725-B2
Application number	US-201715672054-A
Country	US
Kind code	B2
Filing date	Aug 8, 2017
Priority date	May 29, 2013
Publication date	Feb 26, 2019
Grant date	Feb 26, 2019

Abstract

Methods and compositions for somatic cell proliferation as well as increasing viability of somatic cells are provided. The compositions include heparin binding protein isolated from a medium conditioned by growth of pluripotent stem cells, such as, human embryonic stem cells, human embryonic carcinoma cells. The methods include contacting a somatic cell with a heparin binding protein composition for a sufficient period of time to provide for enhanced proliferation and/or viability of the somatic cell as compared to the absence of the heparin binding protein composition.

First claim

What is claimed is:

1. A method for enhancing proliferation of a neural cell, the method comprising:
isolating all heparin binding proteins from a medium conditioned by growth of human embryonic stem cells or human embryonic carcinoma cells, wherein the medium is essentially free of human embryonic stem cells or human embryonic carcinoma cells and wherein the isolating comprises contacting the medium with a solid support conjugated to heparin and eluting the heparin binding proteins bound to the solid support;
contacting the neural cell with a composition comprising all of the heparin binding proteins isolated from the medium conditioned by growth of human embryonic stem cells or human embryonic carcinoma cells,
wherein the contacting is for a period of time sufficient to provide for enhanced proliferation of the neural cell compared to the absence of the heparin binding proteins.

2. The method of claim 1 , wherein the neural cell is a cell of an aged subject.

3. The method of claim 1 , wherein the neural cell is an injured cell.

4. The method of claim 3 , wherein the injury is caused by a disease.

5. The method of claim 1 , wherein the neural cell is a diseased cell.

6. The method of claim 1 , wherein the neural cell is a neural stem cell.

7. The method of claim 1 , wherein the neural cell is a neural progenitor cell.

8. A method of increasing viability of a neuron, the method comprising:
isolating all heparin binding proteins from a medium conditioned by growth of human embryonic stem cells or human embryonic carcinoma cells, wherein the medium is essentially free of human embryonic stem cells or human embryonic carcinoma cells and wherein the isolating comprises contacting the medium with a solid support conjugated to heparin and eluting the heparin binding proteins bound to the solid support;
contacting the neuron with a composition comprising all of the heparin binding proteins isolated from the medium conditioned by growth of human embryonic stem cells or human embryonic carcinoma cells,
wherein the contacting is for a period of time sufficient to provide for increasing viability of the neuron as compared to the absence of the heparin binding proteins.

9. The method of claim 8 , wherein the neuron is a cortical neuron.

10. The method of claim 8 , wherein the neuron is a glutamatergic neuron.

11. The method of claim 8 , wherein the neuron is exposed to a toxin.

12. The method of claim 8 , wherein the toxin is amyloid beta globulomer.

Assignees

• Univ California

Inventors

• Conboy Irina M
• Conboy Michael J
• Yousef Hanadie
• Schaffer David V

Classifications

• C12N2502/02

  embryonic cells · CPC title

• C12N5/0619 Primary

  Neurons · CPC title

• C12N5/0659

  Satellite cells · CPC title

• C12N2501/91

  Heparin · CPC title